Want to see TSE:IZO full AI Analyst Report?
Izotropic (IZO) AI Stock Analysis
Izotropic
(CNQX:IZO)
The score is primarily constrained by weak financial performance (pre-revenue operations, persistent losses, negative free cash flow) and elevated balance-sheet risk from ongoing negative equity and rising debt. Technicals add further pressure with a clear downtrend below major moving averages and negative MACD, while valuation metrics are not helpful due to negative earnings and no dividend support.
Izotropic (IZO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 7.25M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.67K
- Price to Earnings (P/E)
- -4.1
- Beta (1Y)
- 0.04
- Revenue Growth
- ―
- EPS Growth
- 10.32%
- Country
- Canada
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Izotropic Business Overview & Revenue Model
Company Description
Izotropic Corporation operates as a MedTech enterprise, concentrating on the commercialization of diagnostic solutions for breast cancer. Their primary focus lies in developing and offering a breast CT imaging system alongside a 3D CT breast imaging...
How the Company Makes Money
Izotropic’s intended revenue model is primarily tied to commercializing its IzoView Breast CT system in clinical markets. This would typically include revenue from selling or leasing imaging systems to hospitals and imaging centers and generating fol...
Izotropic Financial Statement Overview
Summary
Pre-revenue with consistently negative gross profit and ongoing losses; while net losses and cash burn improved versus 2022–2023, profitability remains deeply negative. Balance-sheet risk is high due to persistent negative equity that has worsened over time, rising debt, and a very small asset base—raising recapitalization/dilution risk.
Income Statement
7Very NegativeBalance Sheet
4Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -33.36K | -33.36K | -48.90K | -59.07K | -30.88K | -6,872 |
| EBITDA | -1.69M | -1.41M | -2.10M | -1.57M | -5.33M | -6.63M |
| Net Income | -2.18M | -2.18M | -3.14M | -1.56M | -5.66M | -6.67M |
Balance Sheet | ||||||
| Total Assets | 439.78K | 439.78K | 414.73K | 232.38K | 442.11K | 2.27M |
| Cash, Cash Equivalents and Short-Term Investments | 219.71K | 219.71K | 274.11K | 38.60K | 165.69K | 1.86M |
| Total Debt | 3.11M | 3.11M | 2.76M | 2.06M | 2.14M | 2.03M |
| Total Liabilities | 6.06M | 6.06M | 5.27M | 4.08M | 3.52M | 2.64M |
| Stockholders Equity | -5.63M | -5.63M | -4.86M | -3.85M | -3.07M | -374.59K |
Cash Flow | ||||||
| Free Cash Flow | -851.25K | -851.25K | -637.37K | -593.57K | -3.30M | -4.79M |
| Operating Cash Flow | -851.25K | -851.25K | -636.23K | -593.57K | -3.27M | -4.76M |
| Investing Cash Flow | 0 | 0 | -1,140 | 0 | -36.18K | -24.23K |
| Financing Cash Flow | 793.63K | 793.63K | 872.78K | 468.18K | 1.61M | 2.58M |
Izotropic Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.20, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.59 is Neutral, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:IZO.
Izotropic Peers Comparison
Overall Rating
TSE:VPT46Neutral- TSE:IZO42Neutral
TSE:BUX40Underperform
TSE:EDT40Underperform
TSE:SONA40Underperform
TSE:PINK38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:VPT | 46Neutral | CAD 15.43M | -6.13 | 56.40% | ― | 89.06% | 37.62% |
| TSE:IZO | 42Neutral | CAD 9.76M | -4.13 | 40.45% | ― | ― | 10.32% |
| TSE:BUX | 40Underperform | CAD 50.05M | -34.81 | -250.77% | ― | -82.05% | 23.73% |
| TSE:EDT | 40Underperform | CAD 303.48M | -8.01 | 51.23% | ― | 1.46% | -64.85% |
| TSE:SONA | 40Underperform | CAD 34.38M | -13.08 | 448.05% | ― | ― | 24.65% |
| TSE:PINK | 38Underperform | CAD 27.62M | -1.41 | -303.05% | ― | 35.27% | 58.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:IZO | Izotropic Corp | 0.14 | -0.33 | -70.21% | |
| TSE:EDT | Spectral Medical (Edtxf) | 1.03 | -0.44 | -29.93% | |
| TSE:BUX | BioMark Diagnostics | 0.47 | 0.13 | 38.24% | |
| TSE:PINK | Perimeter Medical Imaging Ai Inc | 0.18 | -0.05 | -23.40% | |
| TSE:SONA | Sona Nanotech, Inc | 0.28 | -0.33 | -54.10% | |
| TSE:VPT | VentriPoint Diagnostics | 0.08 | -0.02 | -20.00% |
Izotropic Corporate Events
Izotropic Raises $150,000 in Private Placement to Support Breast Imaging Push
PositiveIzotropic Corporation has completed a non-brokered private placement, issuing 750,000 units at $0.20 per unit for gross proceeds of $150,000. Each unit comprises one common share and a transferable warrant allowing the purchase of an additional share...
Izotropic Launches Strategic Private Placement to Fund Working Capital
PositiveIzotropic Corporation plans to complete a non-brokered private placement with a strategic investor, issuing 750,000 units at $0.20 per unit for gross proceeds of up to $150,000. Each unit comprises one common share and one transferable warrant, with...
Izotropic Grants RSUs to Consultants to Drive Global Expansion of Breast CT Platform
PositiveIzotropic Corporation has granted 750,000 Restricted Share Units to various consultants to support financing and broader business development efforts tied to the commercialization of its IzoView breast CT imaging system. The consultants will assist i...
Izotropic Grants RSUs to Consultants, Keeps Dilution in Check
PositiveIzotropic Corporation has granted 750,000 restricted share units to five non‑insider consulting entities at an exercise price of $0.24 per share, under its previously shareholder‑approved long‑term incentive and stock option plans....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026